{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:50:02Z","timestamp":1782485402567,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jpsychires.2025.11.021","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:43:17Z","timestamp":1764142997000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["New treatments for OCD? Evidence for cannabinoids and psychedelics"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4357-5184","authenticated-orcid":false,"given":"Michael","family":"Van Ameringen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Hopkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2025.11.021_bib1","series-title":"Presented at the 2023 American Society of Clinical Psychopharmacology 2023","article-title":"Psilocybin for the treatment of obsessive compulsive disorder (OCD)","author":"Allen","year":"2023"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib6","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial","volume":"16","author":"Bonn-Miller","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39812-0","article-title":"Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey","volume":"13","author":"Buot","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1176\/appi.neuropsych.16030053","article-title":"Refractory OCD due to thalamic infarct with response to dronabinol","volume":"29","author":"Cooper","year":"2017","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/brain\/awab406","article-title":"Models of psychedelic drug action: modulation of cortical-subcortical circuits","volume":"145","author":"Doss","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib15","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r13085","article-title":"Women are at greater risk of OCD than men","volume":"81","author":"Fawcett","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib16","doi-asserted-by":"crossref","DOI":"10.1017\/S146114570800847X","article-title":"The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive\u2013compulsive disorder","volume":"11","author":"Flaisher-Grinberg","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.11.021_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/appi.ajp.20230682","article-title":"Psilocybin: from psychiatric pariah to perceived panacea","volume":"182","author":"Fonzo","year":"2025","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/j.1552-4604.1981.tb02618.x","article-title":"Single\u2010dose study of nabilone in anxious volunteers","volume":"21","author":"Glass","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/srep44468","article-title":"Patterns of default mode network deactivation in obsessive compulsive disorder","volume":"7","author":"Gon\u00e7alves","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-Associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jad.2015.10.048","article-title":"Mental health symptom severity in cannabis using and non-using veterans with probable PTSD","volume":"190","author":"Johnson","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/can.2018.0049","article-title":"The endocannabinoid system: a new treatment target for obsessive compulsive disorder?","volume":"4","author":"Kayser","year":"2019","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JCP.0000000000001179","article-title":"Cannabinoid augmentation of exposure-based psychotherapy for obsessive-compulsive disorder","volume":"40","author":"Kayser","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/da.23032","article-title":"Acute effects of cannabinoids on symptoms of obsessive\u2010compulsive disorder: a human laboratory study","volume":"37","author":"Kayser","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib27","first-page":"S55","article-title":"Anxiolytic effects of an oral cannabinoid in patients with anxiety (abstract)","volume":"13","author":"Lee","year":"2009","journal-title":"Eur J Pain, Supp."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib28","article-title":"Psychedelics, OCD and related disorders: setting methodological strategies for future studies","volume":"45","author":"Leuzzi","year":"2025","journal-title":"J. Obsessive Compuls. Relat. Disord."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn4036","article-title":"The endocannabinoid system in guarding against fear, anxiety and stress","volume":"16","author":"Lutz","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/psychoactives4020016","article-title":"Medicinal cannabis use among people with obsessive compulsive disorder: changes in quality of life after three months","volume":"4","author":"Lynskey","year":"2025","journal-title":"Psychoactives"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib32","series-title":"Presentation at Patients out of Time Conference, Tucson, AZ","article-title":"Medical cannabis as treatment for chronic combat PTSD: promising results in an open pilot study","author":"Mashiah","year":"2012"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jad.2020.09.124","article-title":"Acute effects of cannabis on symptoms of obsessive-compulsive disorder","volume":"279","author":"Mauzay","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.863552","article-title":"Using a MDMA- and LSD-Group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders","volume":"13","author":"Oehen","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2025.152619","article-title":"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: a pharmacological challenge study","volume":"142","author":"Pellegrini","year":"2025","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib39","series-title":"Presented at the International College of Obsessive Compulsive and Related Disorders (ICOCS)-Obsessive-Compulsive Research Network of the ECNP (OCRN) 2024 Meeting: next Generation Treatments for Obsessive Compulsive and Related Disorders","article-title":"Psilocybin in OCD","author":"Pittenger","year":"2024"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib40","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/hbm.22371","article-title":"Reduced functional connectivity within the limbic cortico\u2010striato\u2010thalamo\u2010cortical loop in unmedicated adults with obsessive\u2010compulsive disorder","volume":"35","author":"Posner","year":"2013","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/nc\/niad001","article-title":"Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives","author":"Rankaduwa","year":"2023","journal-title":"Neurosci. Conscious"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2021.152223","article-title":"Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of randomised controlled trials","volume":"106","author":"Reid","year":"2021","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib43","series-title":"Presented at the International Conference on Integrative Medicine, Jerusalem, Israel","article-title":"Medical marijuana\/cannabis use in patients with post-traumatic stress disorder","author":"Reznik","year":"2011"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","article-title":"Preliminary, open-label, pilot study of add-on oral \u03949-tetrahydrocannabinol in chronic post-traumatic stress disorder","volume":"34","author":"Roitman","year":"2014","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review","volume":"20","author":"Sarris","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1176\/appi.ajp.2007.07061016","article-title":"Improvement in refractory obsessive compulsive disorder with dronabinol","volume":"165","author":"Schindler","year":"2008","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108586","article-title":"Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics","volume":"191","author":"Schlag","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib49","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.focus.19402","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"19","author":"Skapinakis","year":"2021","journal-title":"Focus"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib51","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","article-title":"5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex","volume":"17","author":"Vaidya","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdbs.2023.07.001","article-title":"The role of the dorsal anterior cingulate cortex in obsessive-compulsive disorder","volume":"3","author":"van de Veerdonk","year":"2023","journal-title":"Deep Brain Stimulation"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib53","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.euroneuro.2015.12.005","article-title":"Brain circuitry of compulsivity","volume":"26","author":"van den Heuvel","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib54","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib55","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib56","article-title":"Mediating role of rumination and negative affect in the effect of mind-wandering on symptoms in patients with obsessive-compulsive disorder","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.11.021_bib57","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.4088\/JCP.14m09475","article-title":"Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder","volume":"76","author":"Wilkinson","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.11.021_bib58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2018.12.009","article-title":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: a network meta-analysis","volume":"90","author":"Zhou","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625007253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625007253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:24:15Z","timestamp":1782483855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395625007253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"alternative-id":["S0022395625007253"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.11.021","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments for OCD? Evidence for cannabinoids and psychedelics","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}